CTRI/2018/01/011597进行中（未招募）4 期
A prospective, multi-center, randomized, post marketing clinical study comparing Obturaâ?¢ vascular closure device versus manual compression to evaluate safety and performance in patients who have undergone femoral artery puncture procedure. - Obturaâ?¢ VCD-PMS
Meril Life Sciences Pvt Ltd0 个研究点目标入组 174 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •Each potential subject must satisfy all of the following criteria to be enrolled in the study. 1. Both male and female patient aged greater than or equal to 18 years old.
- •2. Patient should be able to provide valid informed signed consent.
- •3. Scheduled for diagnostic or interventional procedure catheterization procedures using a standard 6F and 8F introducer sheath with up to 12 centimeter working length.
- •4. Patient is willing and able to adhere to data collection and follow-up requirements.
排除标准
- •Any potential subject who meets any of the following criteria will be excluded from participating in the study.
- •1. Patients requiring punctured through a vascular graft or a re-puncture at a site previously punctured within 48 hours or planned arterial access at the same access site within 30 days of catheterization.
- •2. Patients with a bleeding disorder, including thrombocytopenia (less than 100,000 platelet count) or thrombasthenia or von WilleBrands disease or significant anemia (Hemoglobin less than 9 miligram per decilitre).
- •3. Patients who bruise or bleed easily or with a history of significant bleeding or platelet disorders.
- •4. Patients with allergy to bovine materials, collagen and/or collagen products, or polyglycolic or polylactic acid polymers.
- •5. Patient with significant medical illness other than study indication as per judgment of principal investigator.
- •6. Patients who are judged by investigator as unable to ambulate post procedure due to physical disability or significant co-morbidity or significant medical illness.
- •7. Patients undergoing thrombolytic therapy or treated with Warfarin within 24 hours prior to catheterization.
- •8. Patients who are known or suspected to be pregnant or is lactating.
- •9. Patients with uncontrolled hypertension with systolic blood pressure greater than 180 milimeter mercury, unless systolic pressure can be lowered by pharmacological agents prior to closure.
- •10. Difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial puncture or evidence of systemic, cutaneous or groin infection.
- •11. History of severe claudication, previous limb amputation below the access site, an iliac or femoral artery lesion greater than 50 percent, previous vascular bypass surgery or stent placement 1 cm from the puncture site.
- •12. Peripheral artery disease patients can be included at operators discretion except if heavy calcification is present at the access site which at the operators discretion precludes insertion of the VCD.
研究者
相似试验
已完成
不适用
Post marketing study to Evaluate safety and efficacy of Suture material (MITSU ABâ?¢ Polyglactin 910) of Meril Endo Surgery Pvt. Ltd in comparision with coated Vicrylâ?¢ Plus Antibacterial (Polyglactin 910) Suture during surgery for closure of surgical incision.CTRI/2017/01/007736Meril EndoSurgery Pvt Ltd122
尚未招募
不适用
A study to evaluate the performance of a pedicle screw system for correction and fusion of Adolescent Idiopathic ScoliosisAdolescent idiopathic scoliosisMusculoskeletal - Other muscular and skeletal disordersSurgery - Other surgeryACTRN12612000316808Kspine20
招募中
不适用
Comparison of HF10 therapy combined with Conventional Medical Managment (CMM) to CMM alone in the treatment of chronic back paiISRCTN87648175evro Corp300
招募中
不适用
Evaluation of the Effect of Intradermal Dihydroquin Dos on Providing Sedation for Patients with Digestive DiseaseEffect of Intradermal Dosage Injection (PCDX).Diseases of the digestive system(K50-K52)IRCT20160103025821N6Tabriz University of Medical Sciences1,650
进行中（未招募）
不适用
A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune?) replacing CNI in a standard care regimen of CNI, mycophenolate mofetil (MMF) and steroids in heart transplant patients - Heart STEUCTR2005-001183-31-BEF. Hoffmann-La Roche Ltd650